MX2020002123A - Sales de ribociclib y formas en estado sólido de las mismas. - Google Patents
Sales de ribociclib y formas en estado sólido de las mismas.Info
- Publication number
- MX2020002123A MX2020002123A MX2020002123A MX2020002123A MX2020002123A MX 2020002123 A MX2020002123 A MX 2020002123A MX 2020002123 A MX2020002123 A MX 2020002123A MX 2020002123 A MX2020002123 A MX 2020002123A MX 2020002123 A MX2020002123 A MX 2020002123A
- Authority
- MX
- Mexico
- Prior art keywords
- ribociclib
- solid state
- state forms
- salts
- forms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente descripción se refiere a formas en estado sólido de Ribociclib, sales de Ribociclib que incluyen succinato de Ribociclib y formas en estado sólido de las mismas, así como a procesos para la preparación de las mismas y composiciones farmacéuticas de las mismas.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762550208P | 2017-08-25 | 2017-08-25 | |
US201762555170P | 2017-09-07 | 2017-09-07 | |
US201762577446P | 2017-10-26 | 2017-10-26 | |
US201762593319P | 2017-12-01 | 2017-12-01 | |
PCT/US2018/047434 WO2019040567A1 (en) | 2017-08-25 | 2018-08-22 | RIBOCICLIB SALTS AND SOLID STATE FORMS THEREOF |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020002123A true MX2020002123A (es) | 2020-09-18 |
Family
ID=63449728
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020002123A MX2020002123A (es) | 2017-08-25 | 2018-08-22 | Sales de ribociclib y formas en estado sólido de las mismas. |
Country Status (10)
Country | Link |
---|---|
US (2) | US11155545B2 (es) |
EP (2) | EP4327880A3 (es) |
KR (1) | KR102715956B1 (es) |
CA (1) | CA3073936A1 (es) |
ES (1) | ES2968174T3 (es) |
HR (1) | HRP20240026T1 (es) |
IL (1) | IL272859A (es) |
MX (1) | MX2020002123A (es) |
SI (1) | SI3672968T1 (es) |
WO (1) | WO2019040567A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3231805B1 (en) | 2014-12-12 | 2020-03-04 | Crystal Pharmatech Co. Ltd. | Salt of pyrrolo[2,3-d]pyrimidine compound and novel polymorph of salt |
CA3048036A1 (en) | 2018-07-02 | 2020-01-02 | Apotex Inc | Novel crystalline form of ribociclib succinate |
WO2020225827A1 (en) * | 2019-05-08 | 2020-11-12 | Mylan Laboratories Limited | Novel polymorphs of ribociclib succinate |
CN112010857B (zh) * | 2019-05-30 | 2021-11-05 | 常州制药厂有限公司 | 一种瑞博西尼单丁二酸盐的晶型 |
CN112375081B (zh) * | 2020-11-23 | 2022-04-12 | 中国医学科学院医药生物技术研究所 | 具有抑制CDK4、6或9活性的吡咯[2,3-d]嘧啶衍生物及其制备方法和应用 |
EP4313987A2 (en) | 2021-04-01 | 2024-02-07 | KRKA, d.d., Novo mesto | Process for the preparation of ribociclib and pharmaceutically acceptable salts thereof |
WO2024115680A1 (en) | 2022-12-01 | 2024-06-06 | Krka, D.D., Novo Mesto | Ribociclib salts and formulations thereof |
WO2024201299A1 (en) | 2023-03-27 | 2024-10-03 | Novartis Ag | Method of treating early breast cancer with ribociclib in combination with an aromatase inhibitor |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2331547T3 (da) | 2008-08-22 | 2014-11-03 | Novartis Ag | Pyrrolopyrimidinforbindelser som CDK-inhibitorer |
AR083797A1 (es) * | 2010-11-10 | 2013-03-20 | Novartis Ag | Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos |
EP3231805B1 (en) | 2014-12-12 | 2020-03-04 | Crystal Pharmatech Co. Ltd. | Salt of pyrrolo[2,3-d]pyrimidine compound and novel polymorph of salt |
CN105111215B (zh) * | 2014-12-12 | 2019-06-18 | 苏州晶云药物科技股份有限公司 | 一种周期蛋白依赖性激酶抑制剂的晶型及其制备方法 |
EP3156406A1 (en) | 2015-10-14 | 2017-04-19 | ratiopharm GmbH | Crystalline forms of ribociclib free base |
WO2019150181A1 (en) * | 2018-02-05 | 2019-08-08 | Biophore India Pharmaceuticals Pvt Ltd | Improved process for the preparation of 7-cyclopentyl-n, n-dimethyl-2-(5-(piperazin-1-yl) pyridin-2-ylaminuteso)-7h-pyrrolo[2,3-d] pyrimidine-6-carboxamide succinate (ribociclib succinate) and its crystalline forms thereof |
TWI675662B (zh) * | 2018-05-17 | 2019-11-01 | 中化合成生技股份有限公司 | 瑞博西尼琥珀酸鹽(Ribociclib succinate salt)晶型B、C及D與其衍生物,以及其等之製造方法與藥物組合物 |
US20230042479A1 (en) | 2019-01-23 | 2023-02-09 | Novartis Ag | New crystalline forms of a succinate salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine -6-carboxylic acid dimethylamide |
-
2018
- 2018-08-22 HR HRP20240026TT patent/HRP20240026T1/hr unknown
- 2018-08-22 EP EP23205642.4A patent/EP4327880A3/en active Pending
- 2018-08-22 KR KR1020207008143A patent/KR102715956B1/ko active IP Right Grant
- 2018-08-22 CA CA3073936A patent/CA3073936A1/en active Pending
- 2018-08-22 US US16/641,390 patent/US11155545B2/en active Active
- 2018-08-22 EP EP18762743.5A patent/EP3672968B1/en active Active
- 2018-08-22 WO PCT/US2018/047434 patent/WO2019040567A1/en unknown
- 2018-08-22 MX MX2020002123A patent/MX2020002123A/es unknown
- 2018-08-22 SI SI201831040T patent/SI3672968T1/sl unknown
- 2018-08-22 ES ES18762743T patent/ES2968174T3/es active Active
-
2020
- 2020-02-23 IL IL272859A patent/IL272859A/en unknown
-
2021
- 2021-10-25 US US17/509,140 patent/US20220041598A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4327880A2 (en) | 2024-02-28 |
EP3672968B1 (en) | 2023-11-01 |
WO2019040567A1 (en) | 2019-02-28 |
US11155545B2 (en) | 2021-10-26 |
US20220041598A1 (en) | 2022-02-10 |
IL272859A (en) | 2020-04-30 |
KR20200074942A (ko) | 2020-06-25 |
US20200190084A1 (en) | 2020-06-18 |
ES2968174T3 (es) | 2024-05-08 |
HRP20240026T1 (hr) | 2024-03-29 |
EP4327880A3 (en) | 2024-05-22 |
EP3672968A1 (en) | 2020-07-01 |
KR102715956B1 (ko) | 2024-10-10 |
CA3073936A1 (en) | 2019-02-28 |
SI3672968T1 (sl) | 2024-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017500408B1 (en) | Heteroaryl compounds as btk inhibitors and uses thereof | |
MX2020002123A (es) | Sales de ribociclib y formas en estado sólido de las mismas. | |
MX2016016666A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
MX2016015093A (es) | Derivados de acido boronico y sus usos terapeuticos. | |
MX2019015744A (es) | Composiciones farmaceuticas. | |
MX2016016143A (es) | Compuestos de [1,2,4]triazol sustituido. | |
MX2022010755A (es) | Inhibidores de quinasa y usos de los mismos. | |
MX363347B (es) | Sal de omecamtiv mecarbilo y proceso para preparar la sal. | |
PH12017501539A1 (en) | Disacetoxytubulysin h and analogs thereof | |
MX2016012056A (es) | Procedimiento de compuesto antifungico. | |
MX2017016619A (es) | Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos. | |
MX2016012053A (es) | Procedimiento de compuesto antifungico. | |
GEP201706760B (en) | Novel abexinostate salt, associated crystalline form, preparation method thereof and the pharmaceutical compositions containing same | |
MX2020006596A (es) | Hidroxiisoxazolinas y derivados de estos. | |
PH12020550703A1 (en) | Sulfonamide compounds and use thereof | |
IN2014MU00455A (es) | ||
EA032927B1 (ru) | Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора | |
MX2018000515A (es) | Compuestos fluorados de cbd, composiciones y usos de los mismos. | |
MX363530B (es) | Compuesto de benzoxaborol tricíclico, método de preparación y uso del mismo. | |
MX2017009292A (es) | Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3. | |
IN2014CH00840A (es) | ||
EA201691741A1 (ru) | Фармацевтическая композиция | |
WO2015111004A3 (en) | Improved process for the preparation of chlorophenyl trifluoroethanone | |
MX2015016603A (es) | Composiciones de corticosteroides. | |
MA39877A (fr) | Formes solides d'un composé pharmaceutiquement actif |